All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was delighted to speak to Wendy Osborne, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
In this video, Wendy Osborne discusses the Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). She talks about the results from the phase I/II study that assesses the safety and efficacy of this bicistronic approach, which was designed to overcome CD19 escape and CAR T exhaustion.
Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Educational theme | Tumor intrinsic resistance mechanisms to CAR T-cell therapy in lymphomas
Here, we review tumor intrinsic resistance mechanisms to anti-CD19 CAR T-cell therapy in B-cell lymphomas and discuss potential novel strategies for...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox